Trial Profile
Safety and pharmacodyanamic effects of eculizumab in patients with paroxysmal nocturnal hemoglobinuria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 May 2016
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Pharmacodynamics
- 25 May 2016 New trial record